Jiangzhong Pharmaceutical (600750) is related to Crimycin. Clorimycin is a macrolide antibiotic that treats bacterial infections. In addition to being effective against drug-resistant gram-positive bacteria, clorimycin is also effective against bacteria that produce some beta-lactamases, and is also very active against some gram-negative bacteria and the fungus Candida albicans. In addition, a domestic patent authorizes the use of corimycin in the treatment of Mycobacterium tuberculosis infection. Carrimycin has the advantages of low toxicity, small dosage, less frequent administration, and convenient administration. It is the first choice for patients pursuing safe and effective drugs within the scope of indications.
Jiangzhong Pharmaceutical (600750): On August 6, 2010, Jiangxi Tonglian Dongfeng Pharmaceutical Co., Ltd. launched a production line project with an annual output of 200 million tablets of the national first-class new drug Crimycin Tablets for Leping The construction of the largest pharmaceutical and chemical industry base in Jiangnan has been written in great detail. The new factory construction project of Jiangxi Tonglian Dongfeng Pharmaceutical Co., Ltd. covers an area of ??20. The construction area is 63.87 million square meters. The total investment is 4.05 million square meters and 400 million yuan. Among them, 240 million yuan was invested in non-penicillin projects such as a 3,000-ton amoxicillin API synthesis production line, an amoxicillin capsule filling production line with an annual output of 5 billion capsules, and a 200 million national first-class new drug colimycin tablets production line annually; investment 200 million yuan to relocate the penicillin powder injection preparation workshop, with an annual output of 1,400 tons of penicillin powder, 200 tons of penicillin refined freeze-dried powder, 200 tons of sulbactam sodium, 50 tons of penicillin powder, 100 million penicillin freeze-dried powder, and 100 million cephalosporins , 1 billion penicillin powder, etc. The park project complies with national industrial policies and is comprehensively aligned with the construction plan of the Poyang Lake Ecological Economic Zone. The product market is broad and the technology content is high. Crimycin is jointly developed by Shenyang United Group Co., Ltd. and the Institute of Medical Biotechnology of the Chinese Academy of Medical Sciences using genetic recombination technology. The national new drug is the first antibiotic with independent intellectual property rights, filling a domestic gap. It has three national patents and is a key research project of the National 863 and Tenth Five-Year Plan.